# Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

> **NCT06040177** · PHASE1,PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable
- Portal Vein Tumor Thrombus
- Immune Checkpoint Inhibitors

## Interventions

- **DRUG:** Cadonilimab
- **RADIATION:** Stereotactic radiotherapy
- **DRUG:** Renvatinib

## Key facts

- **NCT ID:** NCT06040177
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-02
- **Primary completion:** 2023-02-02
- **Final completion:** 2025-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06040177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06040177, "Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06040177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*